Nausea, vomiting, and gastrointestinal discomfort are among the most common reasons for discontinuation, yet they are frequently underreported in traditional clinical datasets
While IV drips may offer quicker results in certain scenarios, capsules provide a practical and effective way to maintain elevated levels of this crucial antioxidant over time
Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes
Trapp S, Stanford SC
According to FDA prescribing information for Wegovy (semaglutide for weight management), nausea occurs in approximately 44% of patients, while vomiting (24%), diarrhea (30%), constipation (24%), and abdominal pain (20%) are also common
These areas tend to have the biggest impact on maintaining daily stability while food intake is lower